305 related articles for article (PubMed ID: 30926668)
1. Small-molecule factor B inhibitor for the treatment of complement-mediated diseases.
Schubart A; Anderson K; Mainolfi N; Sellner H; Ehara T; Adams CM; Mac Sweeney A; Liao SM; Crowley M; Littlewood-Evans A; Sarret S; Wieczorek G; Perrot L; Dubost V; Flandre T; Zhang Y; Smith RJH; Risitano AM; Karki RG; Zhang C; Valeur E; Sirockin F; Gerhartz B; Erbel P; Hughes N; Smith TM; Cumin F; Argikar UA; Haraldsson B; Mogi M; Sedrani R; Wiesmann C; Jaffee B; Maibaum J; Flohr S; Harrison R; Eder J
Proc Natl Acad Sci U S A; 2019 Apr; 116(16):7926-7931. PubMed ID: 30926668
[TBL] [Abstract][Full Text] [Related]
2. Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
Yuan X; Gavriilaki E; Thanassi JA; Yang G; Baines AC; Podos SD; Huang Y; Huang M; Brodsky RA
Haematologica; 2017 Mar; 102(3):466-475. PubMed ID: 27810992
[TBL] [Abstract][Full Text] [Related]
3. A novel antibody against human factor B that blocks formation of the C3bB proconvertase and inhibits complement activation in disease models.
Subías M; Tortajada A; Gastoldi S; Galbusera M; López-Perrote A; Lopez Lde J; González-Fernández FA; Villegas-Martínez A; Dominguez M; Llorca O; Noris M; Morgan BP; Rodríguez de Córdoba S
J Immunol; 2014 Dec; 193(11):5567-75. PubMed ID: 25355917
[TBL] [Abstract][Full Text] [Related]
4. Discovery of Highly Potent and Selective Small-Molecule Reversible Factor D Inhibitors Demonstrating Alternative Complement Pathway Inhibition in Vivo.
Lorthiois E; Anderson K; Vulpetti A; Rogel O; Cumin F; Ostermann N; Steinbacher S; Mac Sweeney A; Delgado O; Liao SM; Randl S; Rüdisser S; Dussauge S; Fettis K; Kieffer L; de Erkenez A; Yang L; Hartwieg C; Argikar UA; La Bonte LR; Newton R; Kansara V; Flohr S; Hommel U; Jaffee B; Maibaum J
J Med Chem; 2017 Jul; 60(13):5717-5735. PubMed ID: 28621538
[TBL] [Abstract][Full Text] [Related]
5. Small-molecule factor D inhibitors targeting the alternative complement pathway.
Maibaum J; Liao SM; Vulpetti A; Ostermann N; Randl S; Rüdisser S; Lorthiois E; Erbel P; Kinzel B; Kolb FA; Barbieri S; Wagner J; Durand C; Fettis K; Dussauge S; Hughes N; Delgado O; Hommel U; Gould T; Mac Sweeney A; Gerhartz B; Cumin F; Flohr S; Schubart A; Jaffee B; Harrison R; Risitano AM; Eder J; Anderson K
Nat Chem Biol; 2016 Dec; 12(12):1105-1110. PubMed ID: 27775713
[TBL] [Abstract][Full Text] [Related]
6. Design, Synthesis, and Preclinical Characterization of Selective Factor D Inhibitors Targeting the Alternative Complement Pathway.
Karki RG; Powers J; Mainolfi N; Anderson K; Belanger DB; Liu D; Ji N; Jendza K; Gelin CF; Mac Sweeney A; Solovay C; Delgado O; Crowley M; Liao SM; Argikar UA; Flohr S; La Bonte LR; Lorthiois EL; Vulpetti A; Brown A; Long D; Prentiss M; Gradoux N; de Erkenez A; Cumin F; Adams C; Jaffee B; Mogi M
J Med Chem; 2019 May; 62(9):4656-4668. PubMed ID: 30995036
[TBL] [Abstract][Full Text] [Related]
7. SAR443809: a selective inhibitor of the complement alternative pathway, targeting complement factor Bb.
Rajagopal V; Leksa N; Gorham R; Jindal S; Nair S; Knockenhauer K; Chan J; Byun T; Mercadante C; Moore S; Panicker S; Parry G; Storek M
Blood Adv; 2023 Aug; 7(16):4258-4268. PubMed ID: 36897252
[TBL] [Abstract][Full Text] [Related]
8. Be on Target: Strategies of Targeting Alternative and Lectin Pathway Components in Complement-Mediated Diseases.
Dobó J; Kocsis A; Gál P
Front Immunol; 2018; 9():1851. PubMed ID: 30135690
[TBL] [Abstract][Full Text] [Related]
9. A novel CRIg-targeted complement inhibitor protects cells from complement damage.
Qiao Q; Teng X; Wang N; Lu R; Guo L; Zhang X; Du Y; Wang W; Chen S; Wu Q; He G; Wang Y; Hu W
FASEB J; 2014 Nov; 28(11):4986-99. PubMed ID: 25114177
[TBL] [Abstract][Full Text] [Related]
10. Low-molecular weight inhibitors of the alternative complement pathway.
Schubart A; Flohr S; Junt T; Eder J
Immunol Rev; 2023 Jan; 313(1):339-357. PubMed ID: 36217774
[TBL] [Abstract][Full Text] [Related]
11. Discovery of 4-((2
Mainolfi N; Ehara T; Karki RG; Anderson K; Mac Sweeney A; Liao SM; Argikar UA; Jendza K; Zhang C; Powers J; Klosowski DW; Crowley M; Kawanami T; Ding J; April M; Forster C; Serrano-Wu M; Capparelli M; Ramqaj R; Solovay C; Cumin F; Smith TM; Ferrara L; Lee W; Long D; Prentiss M; De Erkenez A; Yang L; Liu F; Sellner H; Sirockin F; Valeur E; Erbel P; Ostermeier D; Ramage P; Gerhartz B; Schubart A; Flohr S; Gradoux N; Feifel R; Vogg B; Wiesmann C; Maibaum J; Eder J; Sedrani R; Harrison RA; Mogi M; Jaffee BD; Adams CM
J Med Chem; 2020 Jun; 63(11):5697-5722. PubMed ID: 32073845
[TBL] [Abstract][Full Text] [Related]
12. C5 inhibition prevents renal failure in a mouse model of lethal C3 glomerulopathy.
Williams AL; Gullipalli D; Ueda Y; Sato S; Zhou L; Miwa T; Tung KS; Song WC
Kidney Int; 2017 Jun; 91(6):1386-1397. PubMed ID: 28139294
[TBL] [Abstract][Full Text] [Related]
13. Compstatin analog Cp40 inhibits complement dysregulation in vitro in C3 glomerulopathy.
Zhang Y; Shao D; Ricklin D; Hilkin BM; Nester CM; Lambris JD; Smith RJ
Immunobiology; 2015 Aug; 220(8):993-8. PubMed ID: 25982307
[TBL] [Abstract][Full Text] [Related]
14. Overactivity of Alternative Pathway Convertases in Patients With Complement-Mediated Renal Diseases.
Michels MAHM; van de Kar NCAJ; Okrój M; Blom AM; van Kraaij SAW; Volokhina EB; van den Heuvel LPWJ
Front Immunol; 2018; 9():612. PubMed ID: 29670616
[TBL] [Abstract][Full Text] [Related]
15. Selectivity of C3-opsonin targeted complement inhibitors: A distinct advantage in the protection of erythrocytes from paroxysmal nocturnal hemoglobinuria patients.
Schmidt CQ; Harder MJ; Nichols EM; Hebecker M; Anliker M; Höchsmann B; Simmet T; Csincsi ÁI; Uzonyi B; Pappworth IY; Ricklin D; Lambris JD; Schrezenmeier H; Józsi M; Marchbank KJ
Immunobiology; 2016 Apr; 221(4):503-11. PubMed ID: 26792457
[TBL] [Abstract][Full Text] [Related]
16. The role of the alternative pathway of complement activation in glomerular diseases.
Łukawska E; Polcyn-Adamczak M; Niemir ZI
Clin Exp Med; 2018 Aug; 18(3):297-318. PubMed ID: 29450785
[TBL] [Abstract][Full Text] [Related]
17. Kidney Diseases Associated With Alternative Complement Pathway Dysregulation and Potential Treatment Options.
Sanghera P; Ghanta M; Ozay F; Ariyamuthu VK; Tanriover B
Am J Med Sci; 2017 Dec; 354(6):533-538. PubMed ID: 29208248
[TBL] [Abstract][Full Text] [Related]
18. Complement activation in diseases presenting with thrombotic microangiopathy.
Meri S
Eur J Intern Med; 2013 Sep; 24(6):496-502. PubMed ID: 23743117
[TBL] [Abstract][Full Text] [Related]
19. A novel C3 mutation causing increased formation of the C3 convertase in familial atypical hemolytic uremic syndrome.
Sartz L; Olin AI; Kristoffersson AC; Ståhl AL; Johansson ME; Westman K; Fremeaux-Bacchi V; Nilsson-Ekdahl K; Karpman D
J Immunol; 2012 Feb; 188(4):2030-7. PubMed ID: 22250080
[TBL] [Abstract][Full Text] [Related]
20. Autoantibodies to complement components in C3 glomerulopathy and atypical hemolytic uremic syndrome.
Józsi M; Reuter S; Nozal P; López-Trascasa M; Sánchez-Corral P; Prohászka Z; Uzonyi B
Immunol Lett; 2014 Aug; 160(2):163-71. PubMed ID: 24491679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
